For the passive immunisation of progeny by active immunisation of sows and gilts to reduce mortality and clinical signs during the first days of life, caused by those E. coli strains, which express the adhesins F4ab (K88ab), F4ac (K88ac), F5 (K99) or F6 (987P) and caused by C. perfringens type C.

Dose to be administered and administration route

Intramuscular use.

Administer 1 dose (2 ml) of vaccine per animal in the neck in the area behind the ear.

Before use, allow the vaccine to reach room temperature. Shake vigorously before use and at intervals during use.

Vaccination scheme:

Primary vaccination: Sows/gilts which have not yet been vaccinated with the product are given a primary injection 6 to 8 weeks before the expected date of farrowing and a second injection 4 weeks later.

Revaccination: A single revaccination is carried out 2 to 4 weeks before the expected date of farrowing.

Adverse reactions

In laboratory studies and field trials:

An increase in body temperature up to 2°C was very commonly observed on the day of vaccination. Reduced activity and lack of appetite on the day of vaccination commonly occurred and/or a sometimes painful and hard swelling up to 10 cm diameter for up to 25 days were very commonly observed at the site of injection.

In post marketing experience:

Hypersensitivity reactions may occur in very rare cases.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).